IP Library Granted Patent US 11,077,433
Granted Patent B2
US 11,077,433 · App. 16/798,954 · Granted Aug 3, 2021

Production of fatty olefin derivatives via olefin metathesis

Inventors: Keith M. Wampler (Santa Monica, CA); Peter Meinhold (Santa Monica, CA); Pedro Coelho (Santa Monica, CA); Vu Bui (Santa Monica, CA); Levente Ondi (Budapest, HU); Hasan Mehdi (Budapest, HU)
Assignee: PROVIVI, INC.
B01J31/2278C07C6/04C07C29/147C07C45/41C07C67/08C07C67/293C07C67/343B01J2231/543B01J2531/64B01J2531/66C07B2200/09C07C2531/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,433
App. No.
16/798,954
Granted
Aug 3, 2021
Kind
B2
Abstract

In one aspect, the invention provides a method for synthesizing a fatty olefin derivative. The method includes: a) contacting an olefin according to Formula I with a metathesis reaction partner according to Formula IIb in the presence of a metathesis catalyst under conditions sufficient to form a metathesis product according to Formula IIIb: and b) converting the metathesis product to the fatty olefin derivative. Each R 1 is independently selected from H, C 1-18 alkyl, and C 2-18 alkenyl; R 2b is C 1-8 alkyl; subscript y is an integer ranging from 0 to 17; and subscript z is an integer ranging from 0 to 17. In certain embodiments, the metathesis catalyst is a tungsten catalyst or a molybdenum catalyst. In various embodiments, the fatty olefin derivative is a pheromone. Pheromone compositions and methods of using them are also described.

Claims (33)

1. A method for synthesizing a compound according to Formula VIb:

the method comprising:

acylating an alkenol according to Formula VIII

to form an acylated alkenol according to Formula IX

 and

contacting the acylated alkenol with an olefin according to Formula I

in the presence of a metathesis catalyst having a structure according to Formula 2a

thereby forming the compound of Formula VIb; wherein:

R 1 is selected from the group consisting of H, C 1-18 alkyl, and C 2-18 alkenyl;

R 2c is C 1-6 acyl,

subscript y is an integer ranging from 0 to 17;

subscript z is an integer ranging from 0 to 17;

M is Mo or W;

R 3a is aryl, heteroaryl, alkyl, or cycloalkyl, each of which is optionally substituted;

R 7a is pyrrolyl, imidazolyl, indolyl, pyrazolyl, azaindolyl, or indazolyl, each of which is optionally substituted;

R 8a is optionally substituted aryl;

R 5a is a hydrogen atom, alkyl, or alkoxy;

R 4b is a hydrogen atom, —O—(C 1-6 alkyl), —CH 2 —O—(C 1-6 alkyl), heteroalkoxy, or —N(C 1-6 alkyl) 2 ; and

R 4c and R 4d are independently a hydrogen atom, C 1-6 alkyl, C 1-6 alkoxy, a halogen atom, —NO 2 , an amide, or a sulfonamide.

2. The method of claim 1 , wherein the alkenol according to Formula VIII is formed by reducing an alkyl ester according to Formula IIb:

wherein R 2b is C 1-8 alkyl.

3. The method of claim 1 , wherein the compound of Formula VIb is selected from (Z)-7-dodecenyl acetate; (E)-7-dodecenal; (Z)-7-decenyl acetate; (Z)-7-hexadecenal; (Z)-7-hexadecenyl acetate; (Z)-7-tetradecenal; (Z)-7-tetradecenyl acetate; (Z)-7-undecenyl acetate; (Z)-10-dodecenyl acetate; (Z)-10-hexadecenyl acetate; (Z)-10-pentadecenal; (Z)-10-pentadecenyl acetate; (Z)-10-tetradecenyl acetate; (Z)-10-tridecenyl acetate; (Z)-9-dodecenal; (Z)-9-dodecenyl acetate; (Z)-9-hexadecenal; (Z)-9-hexadecenyl acetate; (Z)-9-pentadecenyl acetate; (Z)-9-tetradecenal; (Z)-9-tetradecenyl acetate; (Z)-9-tetradecenyl formate; (Z)-9-tetradecenyl nitrate; (Z)-9-tridecenyl acetate; (Z)-9-undecenyl acetate; (Z)-11-hexadecen-1-ol; (Z)-11-hexadecenal; (Z)-11-hexadecenyl acetate; (Z)-11-tetraceden-1-ol; (Z)-11-tetracedenyl acetate; (Z)-13-octadecen-1-ol; and (Z)-13-octadecenal.

4. The method of claim 1 , wherein:

R 7a is pyrrolyl, imidazolyl, pyrazolyl, azaindolyl, or indazolyl, each of which is optionally substituted; and

R 5a is a hydrogen atom.

5. The method of claim 1 , wherein R 3a is phenyl, 2,6-dichlorophenyl, 2,6-dimethylphenyl, 2,6-diisopropylphenyl, 2-trifluoromethylphenyl, pentafluorophenyl, tert-butyl, or 1-adamantyl.

6. The method of claim 5 , wherein R 8a is:

7. The method of claim 1 , wherein R 4b is methoxy, R 4c is hydrogen, and R 4d is hydrogen.

8. The method of claim 1 , wherein the metathesis catalyst is:

9. The method of claim 1 , wherein the catalyst is present in an amount less than 0.01 mol % with respect to the olefin or to the metathesis reaction partner.

10. The method of claim 3 , wherein the compound of Formula VIb comprises at least 80% Z olefin.

11. The method claim 1 , wherein acylating the alkenol according to Formula VIII is conducted with an acylating agent selected from the group consisting of acetic anhydride and acetyl chloride.

12. The method claim 11 , wherein 1-5 molar equivalents of the acylating agent with respect to the alkenol according to Formula VIII is used.

Assignments (5)
SECURITY INTEREST Recorded Aug 24, 2023
From: PROVIVI, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064697/0700 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE SECOND UNVENTORS NAME PREVIOUSLY RECORDED AT REEL: 051904 FRAME: 0047. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNNENT. Recorded Apr 7, 2021
From: WAMPLER, KEITH M.; MEINHOLD, PETER; COELHO, PEDRO; BUI, VU
To: PROVIVI, INC.
Reel/Frame 057031/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: WAMPLER, KEITH M.; MAINHOLD, PETER; COELHO, PEDRO; BUI, VU
To: PROVIVI, INC.
Reel/Frame 051904/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: ONDI, LEVENTE; MEHDI, HASAN
To: XIMO AG
Reel/Frame 051904/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: XIMO AG
To: PROVIVI, INC.
Reel/Frame 051904/0361 →
Continuity (4)
Continuation 15721018 · Sep 29, 2017
Continuation 15354916 · Nov 17, 2016
Provisional Application 62257148 · Nov 18, 2015
Related Publication 20200261898A1 · Aug 20, 2020